title: Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4.
authors.affiliation: Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, USA; Program in Molecular and Cell Biology and Genetics, Drexel University College of Medicine, Philadelphia, PA, USA.
authors.forename: Tim N
authors.initials: TN
authors.lastname: Beck
authors.affiliation: Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, USA; Program in Molecular and Cell Biology and Genetics, Drexel University College of Medicine, Philadelphia, PA, USA.
authors.forename: Erica A
authors.initials: EA
authors.lastname: Golemis
authors.affiliation: Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: daniel.geynisman@fccc.edu.
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Geynisman
mesh_terms: D000911:Antibodies, Monoclonal; D051017:Apoptosis Regulatory Proteins; D002292:Carcinoma, Renal Cell; D006801:Humans; D007680:Kidney Neoplasms; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D051017:Apoptosis Regulatory Proteins; D000077594:Nivolumab